Journal
FUTURE MEDICINAL CHEMISTRY
Volume 7, Issue 18, Pages 2451-2467Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc.15.161
Keywords
-
Categories
Funding
- NIH [AG37609]
- NATIONAL INSTITUTE ON AGING [R01AG037609] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Alzheimer's disease (AD) is the most common cause of dementia with no cure at present. Cholesterol metabolism is closely associated with AD at several stages. ACAT1 converts free cholesterol to cholesteryl esters, and plays important roles in cellular cholesterol homeostasis. Recent studies show that in a mouse model, blocking ACAT1 provides multiple beneficial effects on AD. Here we review the current evidence that implicates ACAT1 as a therapeutic target for AD. We also discuss the potential usage of various ACAT inhibitors currently available to treat AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available